Showing results (241-250 of 494) with videos related to
Sort By:
Pageof 50
Oncotarget|June 25, 2019
Plasma lncRNA expression profile as a prognostic tool in <i>BRAF-</i>mutant metastatic melanoma patients treated with BRAF inhibitorTomasz Kolenda, Piotr Rutkowski, Michał Michalak, et al.Medical Oncology (Northwood, London, England)|November 13, 2013
What are the current outcomes of advanced gastrointestinal stromal tumors: who are the long-term survivors treated initially with imatinib?Piotr Rutkowski, Jolanta Andrzejuk, Elżbieta Bylina, et al.Diagnosis (Berlin, Germany)|April 10, 2023
Clouds across the new dawn for clinical, diagnostic and biological data: accelerating the development, delivery and uptake of personalized medicineDenis Horgan, Ettore Capoluongo, France Dube, et al.Contemporary Oncology (Poznan, Poland)|January 26, 2022
Mutational landscape of primary and recurrent Ewing sarcomaPaulina Jagodzińska-Mucha, Paweł Sobczuk, Michał Mikuła, et al.Cancers|September 28, 2023
Mesenchymal Chondrosarcoma from Diagnosis to Clinical TrialsMonika Dudzisz-Śledź, Monika Kondracka, Monika Rudzińska, et al.Annals of Surgery|December 19, 2008
Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodesAlexander C J van Akkooi, Zbigniew I Nowecki, Christiane Voit, et al.Journal of Cancer Research and Clinical Oncology|April 27, 2007
Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs)Piotr Rutkowski, Zbigniew I Nowecki, Maria Debiec-Rychter, et al.International Journal of Molecular Sciences|May 28, 2022
Correlation of Immunological and Molecular Profiles with Response to Crizotinib in Alveolar Soft Part Sarcoma: An Exploratory Study Related to the EORTC 90101 "CREATE" TrialChe-Jui Lee, Elodie Modave, Bram Boeckx, et al.Annals of Surgical Oncology|May 3, 2007
Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumorPiotr Rutkowski, Zbigniew I Nowecki, Wanda Michej, et al.Cancer|June 6, 2024
Long-term efficacy of neoadjuvant-adjuvant targeted therapy in borderline resectable stage IIIB-D and IV melanomaAnna M Czarnecka, Krzysztof Ostaszewski, Piotr J Błoński, et al.Pageof 50